

A randomised prospective phase III comparison of paclitaxel - carboplatin versus docetaxel - carboplatin as first line chemotherapy in stage Ic-IV epithelial ovarian cancer

Submission date 01/07/2001	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 01/07/2001	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 04/01/2012	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr - -

Contact details

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

NCT00003998

Secondary identifying numbers

G57

Study information

Scientific Title

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Ovary

Interventions

1. Docetaxel 75 mg/m² + Carboplatin AUC repeated on day 22 for six cycles
2. Paclitaxel 175 mg/m² + Carboplatin AUC 5 repeated on day 22 for six cycles

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

carboplatin versus docetaxel

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/01/1997

Completion date

01/05/2000

Eligibility

Key inclusion criteria

1. Histologically confirmed epithelial ovarian cancer
2. Female
3. At least 18 years old
4. Stage Ic-IV disease
5. Written informed consent

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Female

Target number of participants

Not provided at time of registration

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1997

Date of final enrolment

01/05/2000

Locations

Countries of recruitment

England

United Kingdom

Study participating centre
UKCCCR Register Co-ordinator
London
United Kingdom
NW1 2DA

Sponsor information

Organisation

Cancer Research UK (CRUK) (UK)

Sponsor details

PO Box 123
Lincoln's Inn Fields
London
United Kingdom
WC2A 3PX
+44 (0)207 317 5186
kate.law@cancer.org.uk

Sponsor type

Charity

Website

<http://www.cancer.org.uk>

ROR

<https://ror.org/054225q67>

Funder(s)

Funder type

Industry

Funder Name

Cancer Research UK

Alternative Name(s)

CR_UK, Cancer Research UK - London, CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Funder Name

Rhone-Poulenc Rorer

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	17/11/2004		Yes	No